Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for obesity and type 2 diabetes, yet substantial variability in weight-loss response remains poorly understood
There are many oral and injectable options now that are FDA-approved, so its best to stick with medications that have been assessed by the standard safety/efficacy channels. On the other hand, many patients are getting results with compounded semaglutide and tirzepatide
**Nutrient Intake** : Protein shakes can be fortified with vitamins and minerals, ensuring that individuals on a calorie-restricted diet still receive essential nutrients
Cost and Accessibility: Semaglutide is FDA-approved and widely available, whereas AOD 9604 is not approved for weight loss, potentially limiting its accessibility and affordability for many individuals
Direct answer: Patients most often ask about safety, duration, weight regain, and risks after several years